Fiche société
Alberta Neurologic Centre
Traitements, essais et publications liés.
Traitements3programmes
Essais2liés
Publications3liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solutionThe object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population. | Migraine | Phase 4 | À vérifier | Italy | À vérifier |
| Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solutionThe object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population. | Migraine | À vérifier | À vérifier | Italy | À vérifier |
| Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solutionThe object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population. | Migraine | Phase 4 | À vérifier | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution | Migraine | Phase 4 | NCT07916571 | Migraine Menopause Study | NOT_YET_RECRUITING |
| Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution | Migraine | À vérifier | NCT05570149 | EMBRACE — EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine. | RECRUITING |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution | Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry. | The journal of headache and pain | ||
| Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution | Cross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry. | The journal of headache and pain | ||
| Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution | Long-term treatment with Eptinezumab in special treatment situations: Real world data. | Journal of the neurological sciences |